Resverlogix Corp.
TSX : RVX

Resverlogix Corp.

April 09, 2007 14:57 ET

Resverlogix Corp. Announces Live Teleconference/Webcast

World leader for ApoA-l technology will review upcoming milestones

CALGARY, ALBERTA--(CCNMatthews - April 9, 2007) - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it will host a live teleconference/webcast with a Q&A session to follow on Wednesday, April 11, 2007 at 11:00 am MDT. The teleconference/webcast will provide securities analysts, shareholders, media and other key stakeholders the opportunity to hear from Donald McCaffrey, President and CEO, who will provide a corporate overview of the emerging dynamics of the atherosclerosis marketplace. Additionally, Mr. McCaffrey will discuss how Resverlogix's key technology, NexVasTM PR, is clearly differentiated and well positioned to address the enormous unmet medical need in this important therapeutic segment. Details of the ongoing strategic analysis with UBS Securities will not be discussed.

The webcast can be accessed at:

www.resverlogix.com, or

http://www.vcall.com/IC/CEPage.asp?ID=115223.

Teleconference participant dial-in number:

Local / International: 416-849-9626

North American Toll- Free: 1-866-585-6398

The web cast will be available on Resverlogix website for replay for a period of 10 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the main underlying cause of cardiovascular disease (CVD). The Company's secondary focus is TGF-Beta Shield™, a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The teleconference will be available for replay until April 21st, 2007.

Archive access information:

Local dial-in number: 416-915-1035

Toll-Free Dial-In Number: 1-866-245-6755

Passcode: 886771

The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information